EMEA-002296-PIP01-17-M02
Key facts
| Invented name |
Alunbrig
|
| Active substance |
brigatinib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0483/2020
|
| PIP number |
EMEA-002296-PIP01-17-M02
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Takeda Pharm A/S
E-mail: paediatrics@tgrd.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|